USPTO serial 79209645
CRESCENDO BIOLOGICS
Reviewed by CopyMark Law Group
Reg. 5488713Status 706Registered
- Filing date
- Status date
- Registration date
- Jun 12, 2018
- Examiner
- LEE, JEANIE H
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with CRESCENDO BIOLOGICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christopher J. Schulte
Christopher J. Schulte Merchant & Gould P.C.P.O. Box 2910Minneapolis, MN 55402-0910United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science; [ chemicals for laboratory research purposes, namely, chemical tests kits for in vitro testing; ] antibodies and antibody fragments for scientific and laboratory use in the nature of biochemical, namely, monoclonal antibodies for in vitro scientific or research use; biochemical, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] veterinary preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes, namely, therapeutic pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] monoclonal antibody therapies for therapeutic purposes, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; ] antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, [ autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, ] for use in the manufacture of therapeutic products | ACTIVE | — |
| 040 | Treatment and transformation of materials for others, namely the custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of medical therapies using antibodies and antibody fragments | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Similar marks named CRESCENDO BIOLOGICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 13, 2026 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 19, 2026 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jul 19, 2026 | INPC | INVALIDATION PROCESSED | — |
| Dec 24, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 3, 2025 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Apr 24, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 24, 2025 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Apr 21, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 4, 2024 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Nov 8, 2024 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Oct 27, 2023 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Aug 19, 2023 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Jun 12, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 6, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 18, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 18, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 12, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 12, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 27, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 27, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 24, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 7, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 7, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 7, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 16, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 1, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 1, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 12, 2018 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 11, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 20, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 19, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 19, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 14, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 23, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 23, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 16, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 15, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 14, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 12, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 8, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |